Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells: Role of c-jun in drug resistance and cell death

Biochemical Pharmacology

Volumn 55, Issue 12, 1998, Pages 1963-1971

  Pourquier, Philippe ^a   Montaudon, Danièle ^a   Huet, Sylvie ^a   Larrue, Annick ^a   Clary, Audrey ^a   Robert, Jacques ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Apoptosis; DNA damage; DNA topoisomerase II; Doxorubicin; Nuclear oncogenes

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG RESISTANCE; FLOW CYTOMETRY; FLUORESCENCE; GENE EXPRESSION; GLIOBLASTOMA; IMMUNOBLOTTING; NONHUMAN; ONCOGENE C JUN; ONCOGENE C MYC; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; BLOTTING, WESTERN; BRAIN NEOPLASMS; DNA DAMAGE; DNA PROBES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, JUN; GENES, MYC; GLIOBLASTOMA; RATS; TUMOR CELLS, CULTURED;

EID: 0032525733     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00006-9     Document Type: Article

References (36)

1. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J. 303:1994;681-695.
2. Capranico G, Zunino F. DNA topoisomerase-trapping antitumour drugs. Eur J Cancer. 28A:1992;2055-2060.
3. De Isabella P, Capranico G, Zunino F. The role of topoisomerase II in drug resistance. Life Sci. 48:1991;2195-2205.
4. Gewirtz D. Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors? Biochem Pharmacol. 42:1991;2253-2258.
5. Gewirtz DA, Orr MS, Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Povirk LF, Bunch RT. Dissociation between bulk damage to DNA and the antiproliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line. Evidence for induction of gene-specific damage and alterations in gene expression. Cancer Res. 53:1993;3547-3554.
6. Bunch RT, Povirk LF, Orr MS, Randolph JK, Fornari FA, Gewirtz DA. Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells. Biochem Pharmacol. 47:1994;317-329.
7. Gewirtz DA. DNA damage, gene expression, growth arrest and cell death. Oncol Res. 5:1994;397-408.
8. Riou JF, Vilarem MJ, Larsen CJ, Riou G. Characterization of the topoisomerase II-induced cleavage sites in the c-myc proto-oncogene. In vitro stimulation by the antitumoral intercalating drug m-AMSA. Biochem Pharmacol. 35:1986;4409-4413.
9. Riou JF, Gabillot M, Riou G. Analysis of topoisomerase II-mediated DNA cleavage of the c-myc gene during HL-60 differentiation. FEBS Lett. 334:1993;369-372.
10. Huet S, Schott B, Robert J. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines. Br J Cancer. 65:1992;538-544.
11. de Tinguy-Moreaud E, Pourquier P, Montaudon D, Robert J. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and resistant rat glioblastoma cells. Anticancer Res. 14:1994;99-104.
12. Schott B, Bennis S, Pourquier P, Ries C, Londos-Gagliardi D, Robert J. Differential overexpression of mdr1 genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vincristine. Int J Cancer. 55:1993;115-121.
13. Modjtahedi N, Lavialle C, Poupon MF, Landin RM, Cassingena R, Monier R, Brison O. Increased level of amplification of the c-myc oncogene in tumors induced in nude mice by a human breast carcinoma cell line. Cancer Res. 45:1985;4372-4379.
14. Ryder R, Nathans D. Induction of c-jun by serum growth factors. Proc Nat Acad Sci USA. 85:1988;8464-8467.
15. Moos M, Gallwitz D. Structure of two human β-actin-related processed genes, one of which is located next to a simple repetitive sequence. EMBO J. 2:1983;757-761.
16. Tso JY, Sun XH, Kao TH, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehyde 3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene. Nucl Acid Res. 13:1985;2485-2502.
17. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning A Laboratory Manual . 1989;Cold Spring Harbor Laboratory Press, New York.
18. Montaudon D, Pourquier P, Denois F, de Tinguy-Moreaud E, Lagarde P, Robert J. Differential stabilization of topoisomerase II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells. Eur J Biochem. 245:1997;307-315.
19. Kim R, Beck WT. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of jun/fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26. Cancer Res. 54:1994;4958-4966.
20. Laemmli UK, Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature 227: 680-385, 1970.
21. Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54:1994;5824-5830.
22. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
23. Petty RD, Cree IA, Sutherland LA, Hunter EM, Lane DP, Preece PE, Andreotti PE. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun. 199:1994;264-270.
24. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res. 49:1989;58-62.
25. de Jong S, Zijlstra JG, de Vries EGE, Mulder NH. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 50:1990;304-309.
26. Glisson B, Gupta R, Smallwood-Kentro S, Ross W. Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line Loss of drug-stimulated DNA cleavage activity . Cancer Res. 46:1986;1934-1938.
27. Spiridonitis CA, Chatterjee S, Petzold SJ, Berger NA. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines. Cancer Res. 49:1989;644-650.
28. Hill BT, Whelan RDH, Hosking LK, Shellard SA, Hinds MD, Mayes J, Zwelling LA. A lack of detectable modifications of topoisomerase II activity in a series of human tumor cell lines expressing only low levels of etoposide resistance. Int J Cancer. 47:1991;899-902.
29. Riou J, Lefevre D, Riou G. Stimulation of the topoisomerase II-induced DNA cleavage sites in the c-myc protooncogene by antitumor drugs is associated with gene expression. Biochemistry. 28:1989;9104-9110.
30. Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FKH, Gewirtz DA. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol. 51:1996;931-940.
31. Rubin E, Kharbanda S, Gunji H, Kufe D. Activation of the c-jun protooncogene in human myeloid leukemia cells treated with etoposide. Mol Pharmacol. 39:1991;697-701.
32. Ritke MK, Yalowich JC. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol. 46:1993;2007-2020.
33. Meichle A, Philipp A, Eilers M. The functions of MYC proteins. Biochim Biophys Acta. 1114:1992;129-146.
34. Ogretmen B, Safa AR. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug-resistant MCF-7/Adr human breast cancer cells. Oncogene. 14:1997;499-506.
35. Sinha BK, Yamazaki H, Eliot HM, Schneider E, Borner MM, O'Connor PM. Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells. Biochim Biophys Acta. 1270:1995;12-18.
36. Han J, Dionne CA, Kedersha NL, Goldmacher VS. p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-14 fibroblasts constitutively expressing c-myc. Cancer Res. 57:1997;176-180.